Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (728)	2/3/2005 11:15:06 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

GEB has continued to act well in spite of the negative general market influence.<g> The stock was able to close yesterday above its DEC.28 H of $4.45 which came after the good Up-day on DEC.27 (On both days the volume was over 400Ks.Yesterday's V was a more modest 125.9Ks ) After the reported insider's Bs in SEP & OCT there were some reported Ss in NOV.<g> But the stock performance has been good since it made its DEC.21 at 2.81 (And that was made at a higher level than its OCT.14 L of 2.37) bigcharts.marketwatch.com Although GEB has continued to show results on the red column, the loss for 2004 is estimated at $0.65/share compared with the $1.86/share in 2003 and the EL for 2005 is expected to show also further reduction, albeit on not such a % improvement.<g> It seems the stock has been responding favorably to the the announcement last week of the acquisition of Inovio, for $10M (3M in cash and 7M in preferred D shares.<g>) They claim that Inovio's use of electroporation for gene therapy and DNA vaccines is a complement to GEB's electroporation program. They plan to start a PI-II DNA vaccine trial. GEB reportedly has around $1 in cash/share and no significant LTD. The long term chart looks interesting. <g> bigcharts.marketwatch.com Bernard